Edit |   |
---|---|
Antigenic Specificity | HGF, Human (Rilotumumab biosimilar) |
Clone | Rilotumumab |
Host Species | Recombinant |
Reactive Species | human |
Isotype | IgG2 kappa |
Format | purified |
Size | 1mg, 5mg |
Concentration | 1mg/ml |
Applications | n/a |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Anti-Human HGF Recombinant Antibody (Rilotumumab). Rilotumumab (previously AMG102) is a human monoclonal antibody designed for the treatment of solid tumors. Rilotumumab was in development by Amgen, Inc. until in November 2014, when Amgen announced it had halted all clinical trials of the compound in advanced gastric cancer (including two Phase III studies) after one of the trials found an increase in the number of deaths in those who were taking rilotumumab and chemotherapy when compared to those who were only administered chemotherapy. |
Immunogen | n/a |
Other Names | Anti-HGF Recombinant Antibody, Research Grade Rilotumumab, Anti-Human HGF Recombinant Antibody(Rilotumumab), , Antibody Drug Analogues, Monoclonal Antibody, YR1200, Research Grade Biosimilars, Biosimilar Antibody |
Gene, Accession # | CAS: 872514-65-3 |
Catalog # | YR1200 |
Price | please inquire |
Order / More Info | HGF, Human (Rilotumumab biosimilar) Antibody from KMD BIOSCIENCE CO. LTD. |
Product Specific References | n/a |